Pathway Genomics' ColoTrue and LynchSyndromeTrue

Pathway Genomics announced it has launched ColoTrue, a comprehensive panel that combines next-generation sequencing with deletion/duplication analysis to detect pathogenic variants in 15 high-risk colorectal cancer susceptibility genes. Pathway has also launched a smaller five-gene panel, LynchSyndromeTrue, which tests genes associated with Lynch syndrome, the most common form of hereditary colon cancer.